Enlivex Therapeutics earnings were -$18.9M for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. The latest ENLV earnings report on Sep 30, 2024 announced Q3 2024 earnings of -$2.6M, down 16% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, ENLV reported annual earnings of -$29.1M, with -6.4% growth.
Enlivex Therapeutics Earnings Reports & History FAQ
What were Enlivex Therapeutics's earnings last quarter?
Enlivex Therapeutics (NASDAQ: ENLV) reported Q3 2024 earnings per share (EPS) of -$0.12, up 62.5% year over year. Total ENLV earnings for the quarter were -$2.60 million. In the same quarter last year, Enlivex Therapeutics's earnings per share (EPS) was -$0.32.
Is Enlivex Therapeutics profitable or losing money?
As of the last Enlivex Therapeutics earnings report, Enlivex Therapeutics is currently losing money. Enlivex Therapeutics's net profit (also called net income) for the twelve months ending Sep 30, 2024 was -$18.93 million, a 30.3% decrease year over year.
What was ENLV's earnings growth in the past year?
As of Enlivex Therapeutics's earnings date in Q1 2025, Enlivex Therapeutics's earnings has grown year over year. ENLV earnings in the past year totalled -$18.93 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.